Exhibit 5
December 31, 2003
Pro-Pharmaceuticals, Inc.
189 Wells Avenue
Newton, Massachusetts 02459
Ladies and Gentlemen:
We have acted as counsel for Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”), under the Securities Act of 1933, as amended (the “Securities Act”), of a registration statement on Form S-3 (the “Registration Statement”), including a prospectus to be filed with the Commission pursuant to Rule 424(b) of Regulation C promulgated under the Securities Act (the “Prospectus”), in connection with the registration, on behalf of the selling stockholders named in the Registration Statement, of up to 7,310,573 shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) comprised of (i) 7,200,960 shares that are currently issued and outstanding (the “Issued Shares”) and (ii) 109,613 shares that are issuable upon the exercise of certain outstanding Common Stock purchase warrants (the “Warrant Shares”). The Registration Statement amends, pursuant to Rule 429 under the Securities Act, the registration statement on Form SB-2 (file no. 333-107112) which previously registered shares of Common Stock on behalf of the selling stockholders named therein.
As counsel to the Company, in connection with this opinion, we have examined and relied upon such records, documents, certificates and other instruments as in our judgment are necessary or appropriate to form the basis for the opinions set forth herein. In our examinations, we have assumed the genuineness of all signatures, the legal capacity of natural persons signing or delivering any instrument, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such latter documents.
Based upon the foregoing, we are of the opinion that:
1. The Issued Shares have been duly authorized and validly issued and are fully paid and non-assessable.
2. The Warrant Shares to be issued upon the exercise of the applicable Common Stock purchase warrants have been duly authorized and, when issued upon such exercise in accordance with the terms of such warrants, will be validly issued, fully paid and non-assessable.
Pro-Pharmaceuticals, Inc.
December 31, 2003
Page 2
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to this firm appearing under the heading “Legal Matters” in the Prospectus. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the General Rules and Regulations of the Commission thereunder.
Very truly yours,
/s/ Perkins Smith & Cohen LLP
Perkins Smith & Cohen LLP